在阿尔茨海默氏症的疾病中神经-阿迪波金交叉声
Bandy Chen1, Marc Schneeberger1,2
1Laboratory of Neurovascular Control of Homeostasis, Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA.
International journal of molecular sciences
|June 19, 2024
概括
体重变化对阿尔茨海默病的风险在整个生命周期中产生不同的影响. 研究脂蛋白或脂肪衍生的蛋白质可能会揭示早期生物标志物和这种神经退行性疾病的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 代谢过程中的代谢.
- 衰老研究研究 衰老研究
背景情况:
- 体重变化与阿尔茨海默病 (AD) 风险有关,中年体重增加增加风险,晚年体重增加具有保护作用.
- 脂肪组织分泌的阿迪波金在从健康衰老过渡到AD等神经系统疾病中的作用尚不清楚.
- 大脑和全身新陈代谢之间存在双向关系,特别是在脂肪组织及其信号分子方面.
研究的目的:
- 研究脂肪组织微环境和分泌的脂蛋白在衰老过程中的参与,区分生物和病理衰老.
- 阐明阿迪波金在过渡到神经系统疾病,特别是阿尔茨海默病中的作用.
- 在衰老和AD的背景下,探索大脑和系统代谢之间的双向通信.
主要方法:
- 这项研究将分析脂肪组织环境和表征关键分泌的阿迪波基因.
- 调查不同年龄段的特定阿迪波金水平和认知功能之间的相关性.
- 使用已建立的衰老和神经退行模型来研究adipokine功能 in vivo.
主要成果:
- 这项研究旨在确定与认知衰退和AD相关的特定阿迪波金.
- 预期的结果包括了解脂肪组织信号的变化如何影响大脑健康.
- 这些发现将突出显示系统代谢在神经退行过程中的作用.
结论:
- 阿迪波金在衰老过程和阿尔茨海默氏症等神经系统疾病的发展中起着至关重要的作用.
- 了解阿迪波金的功能可以导致识别用于早期AD检测的新生物标志物.
- 这项研究可能会发现针对AD治疗代谢途径的新疗法策略.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
06:35Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
Published on: April 5, 2024
942
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
01:19Psychoneuroimmunology: Diabetes and Cancer
27
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
27
01:23Role of Neurotransmitters in Memory
521
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
521